IMMVIRA CO, LTD. specializes in innovative biopharmaceutical technologies aimed at developing effective treatments for various diseases, particularly in the field of oncology and infectious diseases. The company focuses on harnessing the power of oncolytic viruses, which are engineered to selectively target and destroy cancer cells while sparing healthy tissue. This approach not only enhances the efficacy of cancer therapies but also minimizes side effects, providing a promising alternative to traditional treatments. IMMVIRA's pipeline includes a range of products that leverage these advanced viral therapies, showcasing their commitment to addressing unmet medical needs.

In addition to oncolytic virus technology, IMMVIRA is also engaged in the development of immunotherapies that aim to boost the body's immune response against tumors. By utilizing a combination of viral vectors and immune modulators, the company seeks to create synergistic effects that enhance the overall therapeutic impact. Their scientific research emphasizes a deep understanding of the tumor microenvironment and the immune system, which is critical for optimizing treatment strategies. Through these innovative technologies, IMMVIRA CO, LTD. is positioned at the forefront of biopharmaceutical advancements, striving to improve patient outcomes in challenging disease areas.

China

ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors driven by clinical benefits in oncology and non-oncology fields.

1301 Guanguang Road, Shenzhen, Guangdong Province, CN, 518110

IMMVIRA CO, LTD.

Company Details